Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.3%

1 terminated out of 19 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

11%

2 trials in Phase 3/4

Results Transparency

17%

2 of 12 completed with results

Key Signals

2 with results92% success

Data Visualizations

Phase Distribution

10Total
Not Applicable (1)
Early P 1 (2)
P 1 (4)
P 2 (1)
P 3 (2)

Trial Status

Completed12
Recruiting5
Terminated1
Unknown1

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT05121012Recruiting

Synaptic Loss in Multiple System Atrophy

NCT07348276Early Phase 1RecruitingPrimary

First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain

NCT06647641Recruiting

The CurePSP Genetics Program

NCT04539041Phase 1CompletedPrimary

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

NCT07136844Not ApplicableRecruiting

Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology

NCT04363684Recruiting

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

NCT02966145Completed

4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

NCT03030586Completed

ADDIA Proof-of-Performance Clinical Study

NCT04193527Phase 3Completed

A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients

NCT02839642Phase 3CompletedPrimary

Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy

NCT03545126CompletedPrimary

Human CNS Tau Kinetics in Tauopathies

NCT02365922Completed

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

NCT03391765Phase 2TerminatedPrimary

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

NCT02778607UnknownPrimary

PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK

NCT02133846Phase 1Completed

Safety Study of TPI-287 to Treat CBS and PSP

NCT01888185Completed

Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)

NCT03413319Phase 1CompletedPrimary

Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

NCT02103894Phase 1Completed

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02531360Early Phase 1Completed

Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

Showing all 19 trials

Research Network

Activity Timeline